Binds Enzyme Patents (Class 424/146.1)
-
Patent number: 7674458Abstract: Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions, and animal models of conditions associated with a loss of elastic fibers.Type: GrantFiled: June 1, 2007Date of Patent: March 9, 2010Assignee: Massachusetts Eye & Ear InfirmaryInventors: Tiansen Li, Xiaoqing Liu
-
Publication number: 20100040675Abstract: Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase, particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators. When the compounds mimic or enhance the activity of angiostatin, they inhibit angiogenesis. When the compounds inhibit the ability of angiostatin to bind F1 ATP synthase and are either inactive at inhibiting angiogenesis or directly promote angiogenesis, or if they inhibit the activity of angiostatin, they promote angiogenesis. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies.Type: ApplicationFiled: August 11, 2009Publication date: February 18, 2010Inventors: Tammy L. Moser, Salvatore V. Pizzo, Mary S. Stack
-
Patent number: 7662929Abstract: Modulation of Hyaluronan (HA) synthesis and degradation is disclosed by compounds and compositions that are capable of reducing the level of hyaluronan synthase (HAS) or hyaluronidase (HYAL) or the function or activity of HAS or HYAL. The compounds and compositions can also inhibit the expression of genetic material encoding these enzymes. The compounds and compositions comprise nucleic acid molecules and interactive molecules such as antibodies, small molecule inhibitors and substrate analogs of HAS and HYAL. The compounds and compositions are useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.Type: GrantFiled: October 11, 2004Date of Patent: February 16, 2010Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Patent number: 7658922Abstract: This invention relates to the field of immunology and more specifically relates to anti-phytase monoclonal antibodies, immunoassay methods, kits, and reagents, for the detection of a phytase from or derived from E. coli phytase, in particular, Quantum™ phytase. The invention further relates to hybridoma cell lines that produce anti-phytase monoclonal antibodies.Type: GrantFiled: June 3, 2006Date of Patent: February 9, 2010Assignee: AB Enzymes GmbHInventors: Michele Susan Yarnall, Lilian Zeitouni
-
Patent number: 7658923Abstract: Therapeutic methods comprising administering anti-CD26 antibodies for the prevention and treatment of cancers and immune diseases associated with expressing CD26 are provided. The invention describes various types of anti-CD26 antibodies and modes of administration.Type: GrantFiled: February 16, 2007Date of Patent: February 9, 2010Assignees: Board of Regents, The University of Texas System, Dana-Farber Cancer InstituteInventors: Nam Hoang Dang, Chikao Morimoto, Stuart Schlossman
-
Publication number: 20090304685Abstract: A method is disclosed for preventing arterial thrombosis in a subject comprising administering to said subject a therapeutically effective amount of an antibody or epitope-binding fragment or derivative thereof, wherein said antibody, fragment or derivative specifically binds to activated Factor XIIa and prevents the interaction of activated Factor XIIa with its physiological substrates.Type: ApplicationFiled: April 12, 2007Publication date: December 10, 2009Inventor: David J. Pritchard
-
Patent number: 7622117Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.Type: GrantFiled: July 18, 2002Date of Patent: November 24, 2009Assignee: Dynamis Therapeutics, Inc.Inventors: Annette Tobia, Francis Kappler
-
Patent number: 7618624Abstract: A method for regulating the body weight of an animal by feeding it a liposome-encapsulated antibody against lipase.Type: GrantFiled: January 7, 1999Date of Patent: November 17, 2009Assignees: Anitox CorporationInventor: Julio Pimentel
-
Publication number: 20090214420Abstract: The present invention relates generally to a method of screening for the level of neoplastic cell death in a subject. More particularly, the present invention provides a method of screening for the level of neoplastic cell death by detecting the level of expression of telomerase protein and/or gene by dead cells in said subject or in a biological sample derived from said subject. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, assessing the effectiveness of a therapeutic agent or therapeutic regime and predicting the likelihood of a subject either progressing to a more advanced disease state or entering a remissive state. The present invention also provides diagnostic agents useful for detecting telomerase protein and/or nucleic acid molecules.Type: ApplicationFiled: March 31, 2006Publication date: August 27, 2009Applicant: MEDVET SCIENCE PTY. LTD.Inventor: Michael Paul Brown
-
Patent number: 7579447Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.Type: GrantFiled: March 7, 2006Date of Patent: August 25, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
-
Patent number: 7579000Abstract: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.Type: GrantFiled: April 30, 2004Date of Patent: August 25, 2009Assignee: Bayer Schering Pharma AGInventors: David Light, Kirk McLean
-
Patent number: 7579002Abstract: A method for improving animal body weight uniformity or for increasing animal carcass yield is disclosed. The method involves administering an agent to one or a group of animals wherein the agent can reduce bioavailability of a prostaglandin or leukotriene lipid precursor. In a preferred embodiment, the agent employed is an anti-PLA2 antibody.Type: GrantFiled: January 21, 2004Date of Patent: August 25, 2009Assignees: Wisconsin Alumni Research Foundation, Michigan State UniversityInventors: Mark E. Cook, Mingder Yang, Kevin Roberson
-
Publication number: 20090208510Abstract: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.Type: ApplicationFiled: March 11, 2009Publication date: August 20, 2009Applicant: Yeda Research And Development Co. Ltd.Inventors: Irit Sagi, Tamar Danon
-
Publication number: 20090202526Abstract: The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.Type: ApplicationFiled: December 23, 2004Publication date: August 13, 2009Inventor: Jaume Pons
-
Publication number: 20090205062Abstract: The invention relates to genetically manipulated animals that are deficient in the expression of Casapse-9, a protein involved in programmed cell death. The invention further relates to methods for preventing specific types of cell death associated with Caspase-9 activation.Type: ApplicationFiled: December 7, 2007Publication date: August 13, 2009Inventors: Keisuke Kuida, Richard A. Flavell
-
Publication number: 20090202535Abstract: A compound comprising at least a structural entity which binds secretory phospholipase A2 IIA (sPLA2 IIA) or parts of it and more preferably human sPLA2 IIA and which a.) blocks at least one or more sPLA2 IIA function on cell surfaces or in a solution, preferably blood or other body fluids or from tissues, most preferably in vivo, b.) and/or depletes sPLA2 IIA from a solution, preferably blood or other body fluids or from tissues, most preferably in vivo.Type: ApplicationFiled: January 26, 2009Publication date: August 13, 2009Inventors: Ahmed SHERIFF, Birgit VOGT
-
Patent number: 7572589Abstract: A compound capable of specifically binding to pathogen EF-1? but not host EF-1?, wherein the compound binds to any part of an amino acid sequence having at least 70% sequence identity to amino acids 240-230 of SEQ ID NO:22.Type: GrantFiled: November 1, 2002Date of Patent: August 11, 2009Assignee: The University of British ColumbiaInventors: Neil E. Reiner, Artem Tcherkassov, Devki Nandan
-
Patent number: 7569674Abstract: Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and methods of making and using the antibodies are also disclosed.Type: GrantFiled: April 29, 2005Date of Patent: August 4, 2009Assignee: InNexus Biotechnology International LimitedInventors: Heinz Kohler, Sybille Muller
-
Publication number: 20090191194Abstract: The invention relates to the use of agents impeding the expression and/or activity of protein kinase C-alpha (PKC-?), especially for treatment of patients with diabetes and complications such as diabetic nephropathy, retinopathy or neuropathy.Type: ApplicationFiled: December 1, 2008Publication date: July 30, 2009Applicant: Phenos GmbHInventors: Jan MENNE, Hermann Haller
-
Publication number: 20090175882Abstract: This invention provides compounds which specifically inhibit TRPA1 but not other members of the thermoTRP ion channel family. Also provided in the invention are methods of using TRPA1-specific inhibitors to treat or alleviate pains mediated by noxious mechanosensation.Type: ApplicationFiled: February 21, 2007Publication date: July 9, 2009Applicants: IRM LLC, THE SCRIPPS RESEARCH INSTITUTEInventors: Ardem Patapoutian, Timothy J. Jegla
-
Publication number: 20090169564Abstract: Compositions and methods are provided for treating NF-?B-related conditions. In particular, the invention provides a stimulus-inducible IKK signalsome, and components and variants thereof. An IKK signalsome or component thereof may be used, for example, to identify antibodies and other modulating agents that inhibit or activate signal transduction via the NF-?B cascade. IKK signalsome, components thereof and/or modulating agents may also be used for the treatment of diseases associated with NF-?B activation.Type: ApplicationFiled: October 22, 2007Publication date: July 2, 2009Inventors: Frank Mercurio, Hengyi Zhu, Miguel Barbosa, Jian Wu Li, Brion W. Murray
-
Patent number: 7537762Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: September 6, 2006Date of Patent: May 26, 2009Assignees: Amgen Fremont, Inc., Pfizer Inc.Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelley Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Patent number: 7510710Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and/or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and/or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.Type: GrantFiled: January 7, 2005Date of Patent: March 31, 2009Assignee: The Regents of the University of ColoradoInventors: Martha Karen Newell, Evan Newell, Elizabeth Villobos-Menvey
-
Patent number: 7504228Abstract: Methods are provided to specifically modulate the activation of monocytes and/or macrophages. Administration of integrin linked kinase (ILK) blocking agents; compounds that otherwise prevent the binding of natural ILK ligands to ILK; or compounds that prevent expression of, or signaling through ILK exert an anti-inflammatory effect by inhibiting iNOS and COX-2 expression, at the level of transcription by suppressing the activation of NF-?B. The modulation of activation through ILK is used to regulate immune processes at targeted sites, for example to decrease undesirable inflammatory responses.Type: GrantFiled: June 5, 2002Date of Patent: March 17, 2009Assignee: QLT Inc.Inventors: Ljiljana Kojic, Patricia M. Logan, Jeffery J. Wheeler, Kymberley L. Sutton, Gabriel Bela Kalmar
-
Publication number: 20090068194Abstract: The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADI-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human.Type: ApplicationFiled: August 31, 2006Publication date: March 12, 2009Inventors: Jean-Pierre Julien, Makoto Urushitani
-
Publication number: 20090022732Abstract: The teachings relates to the three-dimensional structure of a crystal of a cytochrome protein complexed with a ligand. The three-dimensional structure of four cytochrome P450 2A6-ligand complexes are disclosed. Cytochrome P450 2A6-ligand crystal structures, wherein the ligand is an inhibitor molecule, are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the teachings also relate to methods for utilizing a crystal structure of a cytochrome P450 2A6-ligand complex for identifying, designing, selecting, or testing inhibitors of the cytochrome protein. Such inhibitors are useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by the cytochrome.Type: ApplicationFiled: June 1, 2006Publication date: January 22, 2009Inventors: Eric F. Johnson, Jason K. Yano
-
Publication number: 20090022731Abstract: The invention features methods and compositions benefiting from differential gene expression observed in arthritis-associated B cells.Type: ApplicationFiled: August 16, 2007Publication date: January 22, 2009Applicant: WyethInventors: David Johannes von Schack, Matthew James Whitters, Kyriaki Dunussi-Johannopoulos, Mary Collins, Eugene Lee Brown
-
Patent number: 7479277Abstract: Methods for treating increased intraocular pressure by administering agents that interfere with activities of integrin-linked kinase. By interfering with the ability of integrin-linked kinase to couple integrin signaling to the actin cytoskeleton, aqueous humor outflow facility through the trabecular meshwork is increased and intraocular pressure is decreased.Type: GrantFiled: February 24, 2006Date of Patent: January 20, 2009Assignee: Wisconsin Alumni Research FoundationInventors: Donna M. Peters, Jennifer A. Faralli née Peterson
-
Publication number: 20090017022Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.Type: ApplicationFiled: June 27, 2008Publication date: January 15, 2009Inventors: ROMAN NAWORTH, STEVEN ROSEN
-
Patent number: 7473766Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding a PAK4 serine/threonine kinase. This invention provides an isolated nucleic acid molecule encoding a mutant homolog of the mammalian PAK4 serine/threonine kinase whose amino acid sequence is set forth in FIG. 1A (SEQ ID NO: 2). This invention provides a fusion protein comprising a PAK4 serine/threonine kinase or a fragment thereof and a second peptide. This invention provides a purified mammalian PAK4 serine/threonine kinase. This invention provides a protein comprising substantially the amino acid sequence set forth in FIG. 1A. This invention provides a monoclonal antibody directed to an epitope of a PAK4 serine/threonine kinase. This invention provides a method of inhibiting PAK4 function comprising administering a ligand comprising an amino acid domain which binds to a GTP binding protein so as to inhibit binding of the GTP binding protein to PAK4.Type: GrantFiled: October 24, 2003Date of Patent: January 6, 2009Assignee: The Trustees of Columbia University in the city of New YorkInventor: Audrey Minden
-
Publication number: 20080274103Abstract: The invention relates to compositions and methods for diagnosing and treating cardiac conditions and neurodegenerative diseases using antibodies which specifically recognize and bind to the adenylyl cyclase 5 isoform in the heart and brain. These antibodies demonstrate high specificity to the AC5 isoform and do not cross react to any other AC5 isoform. The invention further relates to methods of delivery of drugs to the site of injured tissue using the antibodies of the present invention.Type: ApplicationFiled: May 26, 2005Publication date: November 6, 2008Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Stephen F. Vatner, Dorothy E. Vatner, Junichi Sadoshima, Jayashree Pain
-
Patent number: 7445794Abstract: The present invention generally relates to systems and methods for treating inflammatory and proliferative diseases, and wounds, using a combination of (1) fatty acid metabolism inhibitors and (2) glycolytic inhibitors and/or UCP and/or Fas inhibitors or antibodies. More particularly, the invention combines an oxirane carboxylic acid compound, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers (i.e., cancers resistant to conventional cancer drug therapies).Type: GrantFiled: April 28, 2005Date of Patent: November 4, 2008Assignee: The Regents of the University of ColoradoInventors: Martha Karen Newell, Elizabeth Villobos-Menuey, Evan Newell
-
Patent number: 7439331Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: June 29, 2006Date of Patent: October 21, 2008Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 7419665Abstract: Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof.Type: GrantFiled: July 29, 2004Date of Patent: September 2, 2008Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Michael J. Pugia, Linda Anderson-Mauser, Solomon H. Murphy, Ronald G. Sommer, Shannon Gleason
-
Patent number: 7416730Abstract: This invention relates to the use of the IL-2 common gamma chain (c?c) and related molecules for the modulation of signal activities controlled by NIK, and some new such molecules.Type: GrantFiled: April 15, 2003Date of Patent: August 26, 2008Assignee: Yeda Research and Development Co. Ltd.Inventors: David Wallach, Parameswaran Ramakrishnan, Taisia Shmushkovich
-
Publication number: 20080175848Abstract: The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGF?, or using agents that inhibit TGF? in combination with agents that degrade excess accumulated extracellular matrix, or at least one agent that degrades excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.Type: ApplicationFiled: October 30, 2007Publication date: July 24, 2008Applicant: University of Utah Research FoundationInventors: Nancy A. Noble, Wayne A. Border
-
Patent number: 7403883Abstract: An in-vitro model apparatus of a human spine and methods for detecting and analyzing substance distribution patterns therein. In one embodiment, the model apparatus includes a column body defining a passageway that substantially mimics the size, shape, and structure of an adult human spinal canal. Also included is a cord structure that may be located and anchored within the passageway. The cord structure substantially mimics the size, shape, and structure of an adult human spinal cord. For example, the cord structure may include connecting elements that resemble nerve roots, dentate ligaments, and the septum posticum of a human spine. The passageway of the model apparatus may be filled with a first fluid that simulates cerebro-spinal fluid (CSF), and a second fluid containing a drug (or simulated drug) may be introduced into the passageway, after which the drug's distribution within the passageway may be analyzed.Type: GrantFiled: October 1, 2004Date of Patent: July 22, 2008Assignee: Medtronic, Inc.Inventors: Kenneth T. Heruth, Mark S. Lent, Michael Hegland
-
Publication number: 20080166357Abstract: The invention provides a human DPP6 which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, muscle skeleton diseases, neurological diseases, urological diseases, reproduction disorders and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, muscle skeleton diseases, neurological diseases, urological diseases, reproduction disorders and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of DPP6 as well as pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: April 28, 2005Publication date: July 10, 2008Inventors: Stefan Golz, Ulf Bruggemeir, Andreas Geerts, Andreas Schubel, Dmitry Zubov
-
Publication number: 20080160023Abstract: The invention relates to a pharmaceutical composition for treating or diagnosing a disorder associated with production of peroxisome in a cell, comprising a polypeptide which has cysteine protease activity and directly processes peroxisomal enzymes targeted by PTS1 or PTS2 signals. Preferably, the polypeptide is encoded by Tysnd1.Type: ApplicationFiled: December 10, 2007Publication date: July 3, 2008Applicants: Riken, Saitama Medical UniversityInventors: Igor Kurochkin, Christian Schoenbach, Yasushi Okazaki
-
Publication number: 20080131442Abstract: IgY antibodies which specifically bind to human telomerase reverse transcriptase (hTERT) can be used to detect hTERT and thereby diagnose cancer. Preparations of the antibodies can be used to reduce hTERT reverse transcriptase activity in in vitro assays and can be used as in vivo therapeutics to treat cancer.Type: ApplicationFiled: June 26, 2006Publication date: June 5, 2008Applicant: SCIENCE APPLICATIONS INTERNATIONAL CORPORATIONInventor: Yan Xiao
-
Patent number: 7378091Abstract: The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity of CA IX, in particular, tumors such as colorectal cancer, renal cell carcinoma (RCC), cervical and other cancers of epithelial origin.Type: GrantFiled: December 2, 2002Date of Patent: May 27, 2008Assignee: Amgen Fremont Inc.Inventors: Jean Gudas, Ian Foltz, Masahisa Handa, Michael L. Gallo
-
Patent number: 7358352Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and; recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: November 13, 2006Date of Patent: April 15, 2008Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 7344713Abstract: A method for the decrease of fat absorption in a mammal, wherein the animal is orally fed an antibody produced against lipase, an enzyme which is required for fat absorption.Type: GrantFiled: July 7, 1997Date of Patent: March 18, 2008Inventor: Julio L. Pimentel
-
Patent number: 7312321Abstract: This invention relates to newly identified polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be stimulators and/or inhibitors which are useful in therapy, to antibodies specific to such peptides, and to production of such polypeptides and polynucleotides.Type: GrantFiled: February 7, 2007Date of Patent: December 25, 2007Assignee: Solvay Pharmaceuticals B.V.Inventors: Willy Deleersnijder, Rico Wiegers, Michael Weske
-
Publication number: 20070269442Abstract: A chimeric therapeutic agent recognizing iNOS utilizing a human/mouse chimeric anti-hiNOS monoclonal antibody having mouse complimentarity-determining regions forming a binding site for iNOS.Type: ApplicationFiled: May 19, 2006Publication date: November 22, 2007Inventors: Robert J. Webber, Douglas S. Webber, Thelma H. Dixon
-
Patent number: 7297336Abstract: Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating patients afflicted with blood coagulation with such ligands, and a nucleic acid that encodes, or a cell that expresses such ligands, are provided.Type: GrantFiled: September 12, 2003Date of Patent: November 20, 2007Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger
-
Publication number: 20070231331Abstract: The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.Type: ApplicationFiled: March 30, 2007Publication date: October 4, 2007Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Nazneen Dewji, S. Jonathan Singer
-
Patent number: 7273610Abstract: Proteins that bind to ET2, such as immunoglobulins that inhibit ET2 with high affinity and selectivity, are provided. The ET2 binding proteins can be used to treat a variety of disorders, including angiogenesis-associated disorders.Type: GrantFiled: August 12, 2004Date of Patent: September 25, 2007Assignee: Dyax Corp.Inventors: Andrew Nixon, Edwin L. Madison
-
Publication number: 20070212358Abstract: A composition comprises plasmin or an enzymatically equivalent derivative thereof and an inhibitor of at least an enzyme that is activatable, directly or indirectly, by plasmin or one of its enzymatically equivalent derivatives. The composition can be used to effect or induce a controlled posterior vitreous detachment (“PVD”) to prevent, treat, or ameliorate a potential complication of a pathological ocular condition. Such a composition can be administered intravitreally.Type: ApplicationFiled: February 23, 2007Publication date: September 13, 2007Inventor: Stephen P. Bartels
-
Patent number: 7258971Abstract: The present invention relates to methods for the diagnosis and treatment of a urological disorder or urological disorders. Specifically, the present invention identifies the differential expression of Carboxypeptidase Z, identified as “8263” gene in tissues relating to urological disorder, relative to their expression in normal, or non-urological disorder disease states, and/or in response to manipulations relevant to a urological disorder. The present invention describes methods for the diagnostic evaluation and prognosis of various urological diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a urological disorder or urological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of urological disorders.Type: GrantFiled: January 14, 2004Date of Patent: August 21, 2007Assignee: Bayer HealthCare AGInventors: Venkateswarlu Karicheti, Inmaculada Silos-Santiago, Scott D. Eliasof